SEARCH

SEARCH BY CITATION

References

  • 1
    Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18(Suppl. 28): 610.
  • 2
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 2325.
  • 3
    Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats: prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 1979; 77: 43343.
  • 4
    Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Gastric cytoprotective property of prostaglandins [Abstract]. Gastroenterology 1977; 72(5): 1121.
  • 5
    Redfern JS, Feldman M. Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins. Gastroenterology 1989; 96(2 Part 2): 596605.
  • 6
    Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 25569.
  • 7
    Ristimaki A, Honkanen N, Jankala H, Siponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 127680.
  • 8
    Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal antiinflammatory drugs. Am J Med 1998; 104: 41321.
  • 9
    Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal antiinflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114: 30719.
  • 10
    Shorrock CJ, Rees WDW. Overview of gastroduodenal mucosal protection. Am J Med 1988; 84(Suppl. 2A): 2534.
  • 11
    Cryer B. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease. In: FeldmanM, ScharschmidtBF, SleisengerMG, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 6th edn. Philadelphia: W. B. Saunders, 1998: 34357.
  • 12
    Hunt RH, Bowen B, Mortensen E, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000; 109: 2016.
  • 13
    Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 2000; 43(2): 3707.
  • 14
    Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 77683.
  • 15
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343(21): 15208.
  • 16
    Clemett D, Goa K. Celecoxib. A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59(4): 95780.
  • 17
    Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. J Am Med Assoc 1999; 282: 19218.
  • 18
    Celecoxib: an NSAID with improved gastrointestinal tolerability. Drug Ther Perspect 2001; 17(5): 15.
  • 19
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis (the CLASS study): a randomized controlled trial. J Am Med Assoc 2000; 284: 124755.
  • 20
    Langman M, Jensen D, Watson D, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. J Am Med Assoc 1999; 282(20): 192933.
  • 21
    Lussier A, Arsenault A, Varady J, De Medicis R, Lussier Y, LeBel E. The use of a 51Cr technique to detect gastrointestinal microbleeding associated with nonsteroidal antiinflammatory drugs. Semin Arthritis Rheum 1988; 17(Suppl. 2): 405.
  • 22
    Ridolfo AS, Crabtree RE, Johnson DW, Rockhold FW. Gastrointestinal microbleeding: comparisons between benoxaprofen and other nonsteroidal antiinflammatory agents. J Rheumatol 1980; (Suppl. 6): 3646.
  • 23
    Aabakken L, Dybdahl JH, Larsen S, Mowinchel P, Osnes M, Quiding H. A double-blind comparison of gastrointestinal effects of ibuprofen standard and ibuprofen sustained release assessed by means of endoscopy and 51Cr-labelled erythrocytes. Scand J Rheumatol 1989; 18: 30713.
  • 24
    Chernish SM, Rosenak BD, Brunelle RL, Crabtree R. Comparison of gastrointestinal effects of aspirin and fenoprofen. Arthritis Rheum 1979; 22(4): 37683.
  • 25
    Lanza FL, Arnold JD. Etodolac, a new nonsteroidal antiinflammatory drug: gastrointestinal microbleeding and endoscopic studies. Clin Rheumatol 1989; 8(Suppl. 1): 515.
  • 26
    Loebl DH, Craig RM, Culic DD, Ridolfo AS, Falk J, Schmid FR. Gastrointestinal blood loss — effect of aspirin, fenoprofen, and acetaminophen in rheumatoid arthritis as determined by sequential gastroscopy and radioactive fecal markers. J Am Med Assoc 1977; 237(10): 97681.
  • 27
    Ryan JR, Vargas R, Clay GA, McMahon FG. Role of misoprostol in reducing aspirin-induced gastrointestinal blood loss in arthritic patients. Am J Med 1987; 83(Suppl. 1A): 414.
  • 28
    Silverstein FE. Improving the gastrointestinal safety of NSAIDs: the development of misoprostol — from hypothesis to clinical practice. Dig Dis Sci 1998; 43(3): 44758.
  • 29
    Gottesdiener K, Schnitzer T, Fisher C, et al. MK-663, a specific COX-2 inhibitor for treatment of osteoarthritis (OA) of the knee [Abstract]. Arthritis Rheum 2000; 42(Suppl. 9): S144.
  • 30
    Malmstrom K, Shahane A, Fricke JR, Ehrich E. MK-0663, a new COX-2 inhibitor: the effect in acute pain using the dental-impaction model [Abstract]. Arthritis Rheum 2000; 43(Suppl. 9): S299.
  • 31
    Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. Nonsteroidal antiinflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114(4): 25763.
  • 32
    Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs. Ann Intern Med 1991; 115(10): 78796.
  • 33
    Taha AS, Sturrock RD, Russell RI. Mucosal erosions in longterm nonsteroidal antiinflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori. Gut 1995; 36: 3346.
  • 34
    Breslow EN, Crowley J. A large sample study of the life table and product limit estimates under random censorship. Ann Stat 1974; 2: 43753.
  • 35
    Harper S, Lee M, Curtis S, Ng J, Watson D, Bolognese J. A lower incidence of upper-GI perforations, ulcers and bleeds (PUBs) in patients treated with etoricoxib vs. nonselective cyclooxygenase inhibitors (NSAIDs). Arthritis Rheum 2001; 44(9 Suppl.): S318.
  • 36
    Lussier A, LeBel E. Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone. Am J Med 1987; 83(Suppl. 4B): 158.
  • 37
    Fosslein E. Adverse effects of nonsteroidal antiinflammatory drugs on the gastrointestinal system. Clin Lab Sci 1998; 28(2): 6781.
  • 38
    Jain K. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Exp Opin Invest Drugs 2000; 9(11): 271723.
  • 39
    Dallob A, Depré M, De Lepeleire I, et al. MK-0663. A highly specific inhibitor of COX-2 in humans. Ann Rheum Dis 2000; 59(Suppl. 1): 331.
  • 40
    Wight N, Gottesdiener K, Wong P, Calder N, Cote J, Hawkey C. Sparing of gastric mucosal prostaglandin synthesis in humans by etoricoxib [Abstract]. Gut 2001; 49(Suppl. III): Abstract 2865.
  • 41
    Shigeta J, Takahashi S, Ishikawa M, Okabe S. Role of cyclooxygenase-2 (COX-2) in the healing of gastric ulcers in rats [Abstract]. Gastroenterology 1998; 114: A285(Abstract).
  • 42
    Schmassmann A, Peskar BM, Stettler C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 1998; 123: 795804.
  • 43
    Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112(2): 38797.
  • 44
    Tatsuguchi A, Sakamoto C, Wada K, et al. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut 2000; 46: 7829.
  • 45
    Hudson N, Balsitis M, Everitt S, Hawkey CJ. Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal anti-inflammatory drugs. Gut 1995; 37: 1914.
  • 46
    Szabo S. Mechanisms of gastric mucosal injury and protection. J Clin Gastroenterol 1991; 13(Suppl. 2): S2134.
  • 47
    Szabo S, Hollander D. Pathways of gastrointestinal protection and repair: mechanisms of action of sucralfate. Am J Med 1989; 86(6A): 2331.
  • 48
    Riegler M, Feil W, Lindroth J, Wong M. MIPSY: Real time morphometry to quantify the time course of rapid epithelial restitution. Pathol Res Pract 1992; 188(4–5): 4438.
  • 49
    Yeomans ND, Skeljo MV. Repair and healing of established gastric mucosal injury. J Clin Gastroenterol 1991; 13(Suppl.): S3741.
  • 50
    Rubin E, Farber J. Pathology. Philadelphia: J. B. Lippincott, 1998.